Pörssitiedote16.09.2024 klo 21.00Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024
Pörssitiedote21.08.2024 klo 12.30Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
Pörssitiedote22.07.2024 klo 09.00NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)
Pörssitiedote18.07.2024 klo 18.45ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE
Pörssitiedote27.06.2024 klo 12.33Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Pörssitiedote28.05.2024 klo 23.00Asarina Pharma AB announces new date for the release of Annual Report for 2023
Pörssitiedote21.05.2024 klo 12.50Asarina Pharma AB announces new date for the release of Annual Report for 2023
Pörssitiedote30.11.2023 klo 11.30Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB
Pörssitiedote23.05.2023 klo 10.02Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
Pörssitiedote22.05.2023 klo 12.15Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Pörssitiedote05.05.2023 klo 14.33Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America
Pörssitiedote18.04.2023 klo 11.39Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
Pörssitiedote01.04.2023 klo 15.20Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome